WCN24-1674 NEFECON TREATMENT RESPONSE IN ASIAN AND WHITE PATIENT POPULATIONS WITH IMMUNOGLOBULIN A NEPHROPATHY: A 2YEAR ANALYSIS OF THE PHASE III NEFIGARD TRIAL by Jonathan Barratt, Jens Kristensen, Andrew Stone, Jürgen Floege, Vladimír Tesař, Hernán Trimarchi, Hong Zhang, Necmi Eren, Alexander Paliege, Heather N. Reich, Brad H. Rovin, Richard Lafayette

Get full text

WCN24-1774 eGFR DECLINE IN PATIENTS WITH IgAN TREATED WITH NEFECON OR PLACEBO: RESULTS FROM THE 2-YEAR NefIgArd PHASE 3 TRIAL by Richard Lafayette, Jens Kristensen, Andrew Stone, Jürgen Floege, Vladimír Tesař, Hernán Trimarchi, Hong Zhang, Necmi Eren, Alexander Paliege, Heather N. Reich, Brad H. Rovin, Jonathan Barratt

Get full text

WCN24-1777 NEFECON TREATMENT PROVIDES KIDNEY BENEFITS FOR PATIENTS WITH IgAN THAT EXTEND TO THOSE WITH LOW LEVELS OF UPCR: A SUB-ANALYSIS OF THE PHASE III NefIgArd TRIAL by Jonathan Barratt, Jens Kristensen, Andrew Stone, Jürgen Floege, Vladimír Tesař, Hernán Trimarchi, Hong Zhang, Necmi Eren, Alexander Paliege, Heather N. Reich, Brad H. Rovin, Richard Lafayette

Get full text

The Efficacy and Safety of Reduced-Dose Oral Methylprednisolone in High-Risk Immunoglobulin A Nephropathy by Dana Kim, Jicheng Lv, Michelle Hladunewich, Vivekanand Jha, Lai Seong Hooi, Helen Monaghan, Sana Shan, Heather N. Reich, Sean Barbour, Laurent Billot, Hong Zhang, Vlado Perkovic, Muh Geot Wong, Adeera Levin, Daniel Cattran, David W. Johnson, David Wheeler, Jürgen Flöge, Mark Woodward, Meg Jardine, Ming-hui Zhao, Rajiv Agarwal, Richard Glassock, Tak Mao Chan, Yangfeng Wu, Zhihong Liu

Get full text